Establishing the onset of action of intranasal corticosteroids: Is there an ideal study design?

Allergy and Asthma Proceedings

Volumn 30, Issue 6, 2009, Pages 595-604

  Katial, Rohit K ^a   Salapatek, Anne Marie M ^b   Patel, Piyush ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b Allied Research International   (Canada)

Author keywords

Allergic rhinitis; Environmental exposure chamber; Intranasal corticosteroids; Onset of action; Park study; Perennial allergic rhinitis; Seasonal allergic rhinitis; Study design; Total nasal symptom score

Indexed keywords

ALLERGEN; BECLOMETASONE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDLINE; METHODOLOGY; PERENNIAL RHINITIS; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; UNITED STATES;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; CLINICAL TRIALS AS TOPIC; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 73649097209     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3291     Document Type: Review

References (44)

1. International Rhinitis Management Working Group. International consensus report on diagnosis and management of rhinitis. Allergy 49(suppl 19):1-34, 1994.
2. Dykewicz MS, and Fineman S. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
3. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. EAACI Position paper. Allergy 55:116-134, 2000.
4. Bousquet J, van Cauwenberge P, Khaltaev N, and ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(suppl 5):S147-S334, 2001.
5. Bousquet J, Chanal I, Alquie MC, et al. Prevention of pollen rhinitis symptoms: Comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study. Allergy 48:327-333, 1993.
6. Fisher WG. Comparison of budesonide and disodium cromoglycate for the treatment of seasonal allergic rhinitis in children. Ann Allergy 73:515-520, 1994.
7. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: Findings from a large online survey. Treat Respir Med 4:439-446, 2005.
8. Stull DE, Roberts L, Frank L, et al. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med Res Opin 23:811-819, 2007.
9. Schenkel E, LaForce C, and Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis: Effective in relieving ocular symptoms. Allergy Clin Immunol Int-J World Allergy Org 19:50-53, 2007.
10. Bielory L, Danzig M, and Gates D. Ocular symptoms of seasonal allergic rhinitis can be treated effectively with an inhaled corticosteroid (mometasone furoate nasal spray). J Allergy Clin Immunol 119:S61, 2007.
11. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 119:1430-1437, 2007.
12. Day JH, Ellis AK, Rafeiro E, et al. Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol 96:263-278, 2006.
13. GlaxoSmithKline. Beconase AQ (beclomethasone dipropionate, monohydrate) Nasal Spray prescribing information. Research Triangle Park, NC, 2005.
14. AstraZeneca. Rhinocort Aqua (budesonide) Nasal Spray prescribing information. Wilmington, DE, 2005.
15. Sepracor, Inc. Omnaris (ciclesonide) Nasal Spray prescribing information. Marlborough, MA, 2007.
16. GlaxoSmithKline. Veramyst (fluticasone furoate) Nasal Spray prescribing information. Research Triangle Park, NC, 2007.
17. GlaxoSmithKline. Flonase (fluticasone propionate) Nasal Spray prescribing information. Research Triangle Park, NC, 2004.
18. Schering Corp. Nasonex (mometasone furoate monohydrate) Nasal Spray prescribing information. Kenilworth, NJ, 2005.
19. sanofi-aventis U.S., LLC. Nasacort AQ (triamcinolone acetonide) Nasal Spray prescribing information. Bridgewater, NJ, 2006.
20. Patel P, Patel D, Kunijibettu S, et al. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ear Nose Throat J 87:340-353, 2008.
21. Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 161:2581-2587, 2001.
22. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olapatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
23. Bousquet J, Van Cauwenberge P, Bachert C, et al. European Academy of Allergy and Clinical Immunology (EAACI); Allergic Rhinitis and its Impact on Asthma (ARIA). Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 58:192-197, 2003.
24. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research (CDER). FDA draft guidance for industry - Allergic rhinitis: Clinical development programs for drug products. Washington, DC: Food and Drug Administration, April 2000.
25. European Medicines Agency and Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. London, England, May 2005. Available online at emca.europa.eu/pdfs/human/ewp/245502en.pdf; last accessed October 20, 2009.
26. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park) setting. Allergy Asthma Proc 20:167-172, 1999.
27. Patel P, Rai K, Benninger PJ, et al. Effect of priming on predose symptom scores in environmental exposure chamber (EEC) study design. J Allergy Clin Immunol 115:S239, 2005.
28. Meltzer EO, Rickard KA, Westlund RE, et al. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. Ann Allergy Asthma Immunol 86:286-291, 2001.
29. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 118:1142-1148, 2006.
30. Meltzer EO, Kunjibettu S, Hall N, et al. Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 98:175-181, 2007.
31. Day JH, Buckeridge DL, Clark RH, et al. A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis. J Allergy Clin Immunol 97:1050-1057, 1996.
32. Fokkens W, Cserhati E, dos Santos JM, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol 89:279-284, 2002.
33. Bende M, Carrillo T, Vona I, et al.Arandomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 88:617-623, 2002.
34. Berkowitz RB, Bernstein DI, LaForce C, et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy 54:64-69, 1999.
35. Day JH, Briscoe MP, Rafeiro E, et al. Onset of action of intranasal budesonide (Rhinocort Aqua) in seasonal allergic rhinitis studies in a controlled exposure model. J Allergy Clin Immunol 105:489-494, 2000.
36. Day JH, Ellis AK, Rafeiro E, et al. Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 96:263-277, 2006.
37. Chervinsky P, Philip G, Malice M-P, et al. Montelukast for treating fall allergic rhinitis: Effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 92:367-373, 2004.
38. Georgitis JW, Meltzer EO, Kaliner M, et al. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. Ann Allergy Asthma Immunol 84:451-459, 2000.
39. Bibi T, Patel P, Dubins D, et al. Less variability of symptom scores for placebo nasal spray in an environmental exposure chamber (EEC) study versus a traditional seasonal allergic rhinitis (SAR) study. J Allergy Clin Immunol 115:S239, 2005.
40. Pozza L, Wall M, Salapatek AM, et al. Seasonal allergic rhinoconjunctivitis studies conducted in an environmental exposure chamber are highly reproducible: Three clinical studies of olopatadine nasal spray demonstrate an identical therapeutic response. Allergy 63(suppl 88):345, 2008.
41. Day JH. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol 103:S395-S399, 1999.
42. Howarth PH. Assessment of antihistamine efficacy and potency. Clin Exp Allergy 29(suppl 3):87-97, 1999.
43. Eccles R. The power of the placebo. Curr Allergy Asthma Rep 7:100-104, 2007.
44. Akerlund A, Andersson M, Leflein J, et al. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol 115:S460-S482, 2005.